Grifols (NASDAQ:GRFS – Get Rating) had its price objective trimmed by Deutsche Bank Aktiengesellschaft from €17.00 ($17.53) to €16.00 ($16.49) in a report issued on Tuesday, The Fly reports. The firm currently has a hold rating on the biotechnology company’s stock.
A number of other research analysts also recently issued reports on GRFS. Jefferies Financial Group started coverage on Grifols in a research note on Monday, July 25th. They issued a hold rating for the company. Morgan Stanley started coverage on Grifols in a research note on Friday, April 8th. They issued an equal weight rating for the company. Finally, Berenberg Bank upped their price objective on Grifols from €20.15 ($20.77) to €20.30 ($20.93) and gave the company a buy rating in a research note on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, Grifols has an average rating of Hold and a consensus price target of $15.77.
Grifols Trading Down 2.1 %
Shares of Grifols stock opened at $8.90 on Tuesday. The company has a market capitalization of $6.12 billion, a P/E ratio of 7.81 and a beta of 0.28. The company has a current ratio of 2.68, a quick ratio of 0.91 and a debt-to-equity ratio of 1.20. The stock has a fifty day simple moving average of $11.19 and a 200 day simple moving average of $11.45. Grifols has a 12-month low of $8.28 and a 12-month high of $15.90.
Institutional Inflows and Outflows
Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.
- Get a free copy of the StockNews.com research report on Grifols (GRFS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.